Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Perrigo Company plc is a drug manufacturers-specialty & generic business based in the US. Perrigo Company shares (PRGO) are listed on the NYSE and all prices are listed in US Dollars. Perrigo Company employs 11,500 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$43.00|
|52-week range||$37.56 - $49.07|
|50-day moving average||$42.80|
|200-day moving average||$44.09|
|Wall St. target price||$51.00|
|Dividend yield||$0.92 (2.15%)|
|Earnings per share (TTM)||$-2.59|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-16)||-2.89%|
|1 month (2021-08-26)||7.63%|
|3 months (2021-06-25)||-8.28%|
|6 months (2021-03-26)||2.36%|
|1 year (2020-09-25)||-4.95%|
|2 years (2019-09-26)||-20.33%|
|3 years (2018-09-26)||71.96|
|5 years (2016-09-26)||95.73|
Valuing Perrigo Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Perrigo Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Perrigo Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.45. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Perrigo Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Perrigo Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $782.9 million.
The EBITDA is a measure of a Perrigo Company's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$5 billion|
|Operating margin TTM||8.37%|
|Gross profit TTM||$1.8 billion|
|Return on assets TTM||2.25%|
|Return on equity TTM||-5.99%|
|Market capitalisation||$5.7 billion|
TTM: trailing 12 months
There are currently 4.6 million Perrigo Company shares held short by investors – that's known as Perrigo Company's "short interest". This figure is 14.2% up from 4.0 million last month.
There are a few different ways that this level of interest in shorting Perrigo Company shares can be evaluated.
Perrigo Company's "short interest ratio" (SIR) is the quantity of Perrigo Company shares currently shorted divided by the average quantity of Perrigo Company shares traded daily (recently around 1.4 million). Perrigo Company's SIR currently stands at 3.15. In other words for every 100,000 Perrigo Company shares traded daily on the market, roughly 3150 shares are currently held short.
However Perrigo Company's short interest can also be evaluated against the total number of Perrigo Company shares, or, against the total number of tradable Perrigo Company shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Perrigo Company's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Perrigo Company shares in existence, roughly 30 shares are currently held short) or 0.0342% of the tradable shares (for every 100,000 tradable Perrigo Company shares, roughly 34 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Perrigo Company.
Find out more about how you can short Perrigo Company stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Perrigo Company.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 39.81
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Perrigo Company's overall score of 39.81 (as at 12/31/2018) is pretty weak – landing it in it in the 83rd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Perrigo Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 2.6/100
Social score: 20.17/100
Governance score: 11.54/100
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Perrigo Company scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Perrigo Company has, for the most part, managed to keep its nose clean.
|Total ESG score||39.81|
|Total ESG percentile||83.16|
|Level of controversy||2|
Dividend payout ratio: 33.04% of net profits
Recently Perrigo Company has paid out, on average, around 33.04% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.23% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Perrigo Company shareholders could enjoy a 2.23% return on their shares, in the form of dividend payments. In Perrigo Company's case, that would currently equate to about $0.92 per share.
While Perrigo Company's payout ratio might seem fairly standard, it's worth remembering that Perrigo Company may be investing much of the rest of its net profits in future growth.
Perrigo Company's most recent dividend payout was on 20 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 1 September 2021 (the "ex-dividend date").
Perrigo Company's shares were split on a 2:1 basis on 25 August 1993. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Perrigo Company shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Perrigo Company shares which in turn could have impacted Perrigo Company's share price.
Over the last 12 months, Perrigo Company's shares have ranged in value from as little as $37.5644 up to $49.0698. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Perrigo Company's is 1.1714. This would suggest that Perrigo Company's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through Consumer Self-Care Americas, Consumer Self-Care International, and Prescription Pharmaceuticals segments. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the brand names of Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, and Dr. Fresh. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 30 countries, primarily in Europe. The Prescription Pharmaceuticals segment develops, manufactures, and markets a portfolio of generic prescription drugs, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, controlled substances, injectable, hormones, oral solid dosage forms, and oral liquid formulations in the United States, as well as pharmaceutical and diagnostic products in Israel.
Everything we know about the Enfusion IPO, plus information on how to buy in.
Everything we know about the Intuity Medical IPO, plus information on how to buy in.
Everything we know about the Pyxis Oncology IPO, plus information on how to buy in.
Everything we know about the AEON Biopharma IPO, plus information on how to buy in.
Everything we know about the IHS Holding Ltd IPO, plus information on how to buy in.
Everything we know about the BT Brands IPO, plus information on how to buy in.
Everything we know about the Immix IPO, plus information on how to buy in.
Everything we know about the Keter Group SA IPO, plus information on how to buy in.
Everything we know about the Theseus Pharmaceuticals IPO, plus information on how to buy in.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq on Sep. 20, 2021
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.